1. Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii

   • Yoshihiko Maehara
   • Eiji Oki
   • Mitsuo Shimada

   Special Article 24 March 2023 Pages: 613 - 624

   

2. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists

   • Takeshi Matsubara
   • Hideki Yokoi
   • Motoko Yanagita

   Invited Review Article 05 March 2023 Pages: 625 - 636

3. Anticancer drug therapy for patients with renal dysfunction

   • Koichi Suyama
   • Yuji Miura

   Invited Review Article 28 March 2023 Pages: 637 - 643

4. Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center

   • Masashi Ando
   • Kazunori Honda
   • Kei Muro

   Original Article Open access 10 March 2023 Pages: 644 - 653

   

5. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant

   • Chikako Nakai
   • Sachiyo Mimaki
   • Katsuya Tsuchihara

   Original Article Open access 01 March 2023 Pages: 654 - 663

   

6. Impact of MIR31HG polymorphisms on risk of breast cancer in Chinese women

   • Ying Wei
   • Xiaolin Wang
   • Xinhan Zhao

   Original Article 08 March 2023 Pages: 664 - 679

   

7. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST

   • Ryugo Teranishi
   • Tsuyoshi Takahashi
   • Yuichiro Doki

   Original Article 27 March 2023 Pages: 680 - 687

   

8. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer

   • Hiroki Nakajima
   • Junpei Yamaguchi
   • Tomoki Ebata

   Original Article 06 March 2023 Pages: 688 - 697

   

9. Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy

   • Yu Imai
   • Fumihiko Urabe
   • Takahiro Kimura

   Original Article 22 February 2023 Pages: 698 - 706

   

10. Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy

    • Takafumi Saito
    • Kazuhiro Matsumoto
    • Mototsugu Oya

    Original Article 17 March 2023 Pages: 707 - 715

    

11. Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone

    • Ashita Ono
    • Takeshi Hashimoto
    • Yoshio Ohno

    Original Article Open access 24 March 2023 Pages: 716 - 723

    

12. Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

    • Shunichi Sugawara
    • Masashi Kondo
    • Yuichiro Ohe

    Correction Open access 17 January 2023 Pages: 724 - 725

13. Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study

    • Renpei Kato
    • Sei Naito
    • Wataru Obara

    Correction Open access 03 April 2023 Pages: 726 - 727